Literature DB >> 8795611

Cholinesterase inhibition in Parkinson's disease.

M Hutchinson, E Fazzini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8795611      PMCID： PMC486563          DOI： 10.1136/jnnp.61.3.324-a

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  6 in total

1.  Tacrine for senile dementia of Alzheimer's or Lewy body type.

Authors:  G K Wilcock; M I Scott
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

2.  Lewy bodies and response to tacrine in Alzheimer's disease.

Authors:  R Levy; S Eagger; M Griffiths; E Perry; M Honavar; A Dean; P Lantos
Journal:  Lancet       Date:  1994-01-15       Impact factor: 79.321

3.  Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease.

Authors:  I Nakano; A Hirano
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

4.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

Authors:  K L Davis; L J Thal; E R Gamzu; C S Davis; R F Woolson; S I Gracon; D A Drachman; L S Schneider; P J Whitehouse; T M Hoover
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

5.  Exacerbation of parkinsonism by tacrine.

Authors:  B R Ott; M C Lannon
Journal:  Clin Neuropharmacol       Date:  1992-08       Impact factor: 1.592

6.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

Authors:  M J Knapp; D S Knopman; P R Solomon; W W Pendlebury; C S Davis; S I Gracon
Journal:  JAMA       Date:  1994-04-06       Impact factor: 56.272
  6 in total
  28 in total

Review 1.  Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders.

Authors:  D I Kaufer
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 2.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  D Aarsland; K Karlsen
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

3.  Apathy in Parkinson's disease.

Authors:  G C Pluck; R G Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

Review 4.  Cholinesterase inhibitors for behavioral disturbance in dementia.

Authors:  E J Daly; W E Falk; P Brown
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

Review 5.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 6.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 7.  Dementia with Lewy bodies: clinical features and treatment.

Authors:  S Campbell; S Stephens; C Ballard
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

8.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

Review 9.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 10.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.